Stockscreener 앱 받기
104.31
3.90%
3.92
시간 외 거래:
104.31
전일 마감가:
$100.39
열려 있는:
$99.42
하루 거래량:
812.06K
Relative Volume:
1.01
시가총액:
$6.66B
수익:
$46.02M
순이익/손실:
$-130.15M
주가수익비율:
-51.06
EPS:
-2.0427
순현금흐름:
$56.08M
1주 성능:
+7.44%
1개월 성능:
+19.76%
6개월 성능:
+61.22%
1년 성능:
+104.33%
1일 변동 폭
$97.16
$105.00
1주일 범위
$97.16
$105.69
52주 변동 폭
$39.60
$105.69
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
104.31 | 6.41B | 46.02M | -130.15M | 56.08M | -2.0427 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-12 | 개시 | Leerink Partners | Outperform |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Aug Chart Watch: Can Protagonist Therapeutics Inc be the next market leader2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
Dinesh Ph Patel Sells 54,641 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics(PTGX.US) Officer Sells US$5.52 Million in Common Stock - Moomoo
Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) March 2026 - Meyka
US High Growth Tech Stocks to Watch Now - simplywall.st
Highs Report: Is Protagonist Therapeutics Inc forming a bullish divergenceWeekly Stock Report & Intraday High Probability Setup Alerts - baoquankhu1.vn
PTGX (NASDAQ: PTGX) option exercise sale of 54,700 shares - Stock Titan
Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi - Seeking Alpha
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $117 - Moomoo
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics - Stocktwits
Wall Street says Johnson and Johnson’s FDA-approved psoriasis drug should create 'significant value' for Protagonist Therapeutics - MSN
Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone - MarketBeat
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
(PTGX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Protagonist Therapeutics wins FDA approval for ICOTYDE and joins Fast 500 ranking - Traders Union
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why - Yahoo Finance
Protagonist Therapeutics (PTGX) Jumps 4.7%: Does the Stock Have More Room to Grow? - Bitget
A Look At Protagonist Therapeutics (PTGX) Valuation After FDA Approval Of ICOTYDE - Yahoo Finance
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock? - Yahoo Finance
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Why Protagonist Therapeutics (PTGX) Is Up 6.6% After First Psoriasis Drug Wins FDA Approval And What's Next - Yahoo Finance
Citigroup Raises Price Target for PTGX to $125, Maintains Buy Ra - GuruFocus
A Look At Protagonist Therapeutics (PTGX) Valuation After ICOTYDE Receives U.S. FDA Approval - simplywall.st
PTGX Analyst Rating Update: Leerink Partners Raises Price Target to $110 | PTGX Stock News - GuruFocus
Protagonist Therapeutics Inc buy JPMorgan Chase & Co. - sharewise.com
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
Protagonist Therapeutics (PTGX) Receives Rating Update from JP M - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Given New $106.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 4.6% Following Analyst Upgrade - MarketBeat
Protagonist Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $125.00 at Citigroup - MarketBeat
Johnson & Johnson-Protagonist Therapeutics partnered new psoriasis pill wins FDA nod, shakes up competition with AbbVie - MSN
Protagonist Therapeutics (PTGX) Sees Target Price Upgrade from B - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Given New $119.00 Price Target at Barclays - MarketBeat
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie - Benzinga
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie - Benzinga
Clear Street raises Protagonist Therapeutics price target on FDA approval By Investing.com - Investing.com Canada
Icotyde’s in; wave of switchers to oral psoriasis Protagonist? - BioWorld MedTech
How an East Bay company picked up $50 million with another $580 million potentially on the way - The Business Journals
Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) Mar 2026 - Meyka
Barclays raises Protagonist Therapeutics stock price target on FDA approval By Investing.com - Investing.com Australia
CEO Moves: Is Protagonist Therapeutics Inc stock good for income investorsQuarterly Risk Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Barclays raises Protagonist Therapeutics stock price target on FDA approval - Investing.com
Jefferies raises Protagonist Therapeutics price target on drug approval By Investing.com - Investing.com India
Jefferies raises Protagonist Therapeutics price target on drug approval - Investing.com
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis TreatmentSlideshow (NASDAQ:PTGX) 2026-03-18 - Seeking Alpha
Protagonist Therapeutics stock gets Truist buy rating reiterated By Investing.com - Investing.com Canada
FDA clears Protagonist Therapeutics ICOTYDE as first-line oral plaque psoriasis treatment - Traders Union
J&J wins FDA nod for plaque psoriasis pill developed with Protagonist - Seeking Alpha
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis - ACCESS Newswire
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):